Evofem Biosciences

Historical price data

Evofem Biosciences is a mission-driven company focused on empowering women through innovative, non-hormonal contraceptive and sexual health products. Its key achievement is the FDA approval and commercial launch of Phexxi®, a first-in-class, on-demand contraceptive gel, complemented by the strategic acquisition of Solosec® for bacterial vaginosis. The company's strategy centers on commercial execution in the U.S., securing international partnerships, and advancing its pipeline based on its pH modulation technology to address significant unmet needs in women's healthcare.

Proprietary vaginal pH modulator technology designed to maintain an acidic environment that is hostile to sperm and certain pathogens, enabling non-hormonal, on-demand contraception and potential prevention of infections like bacterial vaginosis.

Phexxi competes in the crowded contraceptive market by uniquely offering a non-hormonal, on-demand prescription option, a niche not served by daily pills or long-acting devices. In bacterial vaginosis, Solosec competes on convenience with a single-dose regimen, while EVO200 aims to address the high-unmet need of recurrence prevention.